Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants

被引：15
作者：
Schoretsanitis, Georgios [1 ,2 ,3 ]
de Leon, Jose [4 ,5 ,6 ]
Diaz, Francisco J. [7 ]
机构：
[1] Univ Hosp Psychiat, Bern, Switzerland
[2] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany
[3] JARA Translat Brain Med, Aachen, Germany
[4] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[5] Univ Granada, Inst Neurosci, Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
[6] Univ Basque Country, Santiago Apostol Hosp, Biomed Res Ctr Mental Hlth Net CIBERSAM, Vitoria, Spain
[7] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA
来源：
PHARMACOGENOMICS | 2018年 / 19卷 / 10期
关键词：
9-hydroxyrisperidone; ABCB1; CYP2D6; p-glycoprotein; prolactin; risperidone; sex; P-GLYCOPROTEIN; ATYPICAL ANTIPSYCHOTICS; GENETIC POLYMORPHISMS; DRUG-INTERACTIONS; FEMALE-PATIENTS; CO-MEDICATIONS; PHARMACOKINETICS; PHARMACODYNAMICS; METABOLISM; ELEVATION;
D O I：
10.2217/pgs-2018-0053
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The role of sex on the association of plasma prolactin levels with risperidone (R) and 9-hydroxyrisperidone (9-OHR) concentrations is investigated. Methods: Plasma R and prolactin concentrations, CYP2D6 and exon 21 and 26 ABCB1 gene variants were studied in 110 patients. Results: In females, a 1 ng/ml increase in R levels was associated with a significant 1.02% increase in prolactin levels. In males, a 1 ng/ml increase in 9-OHR levels was associated with a significant 1.18% increase in prolactin levels. ABCB1 haplotype 12 had significant but opposite effects in males and females. In the combined sample, 9-OHR, but not R levels had significant effects on prolactin levels. Conclusion: Genes had sex-specific effects on risperidone-associated prolactin elevations.
引用
收藏
页码：815 / 823
页数：9
相关论文
共 58 条
[1]   Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling [J].
Barter, Zoe E. ;
Tucker, Geoffrey T. ;
Rowland-Yeo, Karen .
CLINICAL PHARMACOKINETICS, 2013, 52 (12) :1085-1100
[2]   The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions [J].
Berecz, R ;
Dorado, P ;
De La Rubia, A ;
Cáceres, MC ;
Degrell, I ;
LLerena, A .
CURRENT DRUG TARGETS, 2004, 5 (06) :573-579
[3]   A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A [J].
Bork, JA ;
Rogers, T ;
Wedlund, PJ ;
de Leon, J .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) :469-476
[4]   Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model [J].
Botts, Sheila ;
Diaz, Francisco J. ;
Santoro, Vincenza ;
Spina, Edoardo ;
Muscatello, Maria R. ;
Cogollo, Myladis ;
Castro, Fidel E. ;
de Leon, Jose .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (06) :1453-1458
[5]   In vitro P-glycoprotein affinity for atypical and conventional antipsychotics [J].
Boulton, DW ;
DeVane, CL ;
Liston, HL ;
Markowitz, JS .
LIFE SCIENCES, 2002, 71 (02) :163-169
[6]   Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers [J].
Cabaleiro, Teresa ;
Ochoa, Dolores ;
Lopez-Rodriguez, Rosario ;
Roman, Manuel ;
Novalbos, Jesus ;
Ayuso, Carmen ;
Abad-Santos, Francisco .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2014, 29 (05) :459-469
[7]   Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].
Cascorbi, I ;
Gerloff, T ;
Johne, A ;
Meisel, C ;
Hoffmeyer, S ;
Schwab, M ;
Schaeffeler, E ;
Eichelbaum, M ;
Brinkmann, U ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174
[8]   A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels [J].
de Leon, J. ;
Susce, M. T. ;
Pan, R.-M. ;
Wedlund, P. J. ;
Orrego, M. L. ;
Diaz, F. J. .
PHARMACOPSYCHIATRY, 2007, 40 (03) :93-102
[9]   The dosing of atypical antipsychotics [J].
de Leon, J ;
Armstrong, SC ;
Cozza, KL .
PSYCHOSOMATICS, 2005, 46 (03) :262-273
[10]   The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation [J].
de Leon, J ;
Susce, MT ;
Pan, RM ;
Fairchild, M ;
Koch, WH ;
Wedlund, PJ .
JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) :15-27
123456